Core Insights - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][4] Presentation Details - Jasper will present five posters and one oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting from February 28 to March 3, 2025, in San Diego, CA [1] - The oral presentation titled "Initial Results from BEACON, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Chronic Spontaneous Urticaria (CSU)" is scheduled for March 1, 2025, at 2:55 p.m. PST [2] - Additional poster presentations will cover various aspects of briquilimab's effects, including its ability to induce mast cell depletion and inhibit SCF/c-Kit signaling [2] Mechanism of Action - Briquilimab is an aglycosylated monoclonal antibody that blocks stem cell factor from binding to c-Kit, disrupting survival signals and leading to mast cell depletion through apoptosis [3][4] - This mechanism addresses the underlying inflammatory response in mast cell driven diseases, potentially offering therapeutic benefits for patients with CSU, CIndU, and asthma [4]

Company Overview - Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing briquilimab, a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [1][3] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to the depletion of mast cells and addressing the inflammatory response in these diseases [3] Clinical Development - Jasper is currently conducting clinical studies of briquilimab for patients with CSU, CIndU, and asthma, demonstrating efficacy and safety in previous trials [3] - Positive clinical outcomes have been reported for briquilimab in treating CSU and CIndU [3] Upcoming Events - Jasper's management will present at the Oppenheimer Healthcare Life Sciences Conference on February 11, 2025, at 3:20 p.m. EST, in a fireside chat format [2] - A live webcast of the presentation will be available on Jasper's Investor Relations website, with an archived replay accessible for 30 days post-event [2]

Core Insights - Jasper Therapeutics reported positive preliminary data from the BEACON Phase 1b/2a study of briquilimab, showing rapid and durable clinical responses in patients with chronic spontaneous urticaria (CSU) [2][3][17] - The study demonstrated significant reductions in Urticaria Activity Score over 7 days (UAS7), with a mean change of -26.6 in the 240mg single-dose cohort at 8 weeks [2][6][8] - The company plans to initiate a registrational program for briquilimab in CSU, with a Phase 2b study expected to start in the second half of 2025 [16][17] Study Results - In the BEACON study, 100% of patients in the 240mg single-dose cohort achieved complete responses (UAS7 = 0) at 8 weeks, with 66% maintaining well-controlled disease at 12 weeks [2][6][8] - Multiple dosing regimens at or above 120mg showed UAS7 changes of more than -25 points, indicating substantial clinical activity [2][6][10] - Serum tryptase levels were significantly reduced, with 100% of participants in the 240mg cohort achieving levels below the lower limit of quantification by week 1 [13][14] Safety Profile - Briquilimab was well tolerated, with no dose-limiting toxicities reported and only low-grade adverse events observed [14] - Predictable decreases in neutrophil counts were noted, which generally recovered before subsequent doses [14] Future Plans - Jasper is conducting an open-label extension study for patients transitioning from the BEACON study to a 180mg Q8W dose [15] - The company has submitted for regulatory review of additional BEACON cohorts, including 240mg Q8W and 180mg Q8W following a 240mg induction dose [15][16] - Data from additional cohorts are expected to be presented by mid-2025, further informing the registrational program [16]

Core Viewpoint - Jasper Therapeutics, Inc. is hosting a virtual webinar on January 8, 2025, to present preliminary data from the BEACON study of briquilimab, a novel antibody therapy targeting c-Kit for mast cell driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] - Briquilimab is an aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion and reduction of inflammatory responses [2] - The company has reported positive clinical outcomes for briquilimab in CIndU and is currently conducting clinical studies for its efficacy in CSU, CIndU, and asthma [2] Upcoming Event - The webinar will feature management presentations and remarks from Dr. Thomas B. Casale, a leading investigator in the BEACON study [1]

Core Insights - Jasper Therapeutics has initiated dosing in its Phase 1b/2a clinical study, ETESIAN, to evaluate briquilimab for allergic asthma, marking a significant milestone in its clinical programs targeting mast cell-driven diseases [1][2] Company Overview - Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for chronic mast and stem cell diseases, including chronic urticaria and asthma [5] - Briquilimab has shown efficacy and safety in over 160 participants and healthy volunteers, with clinical outcomes in chronic inducible urticaria (CIndU) and as a conditioning agent in various severe conditions [4][5] Clinical Study Details - The ETESIAN study aims to enroll approximately 30 patients across 7 sites in Canada, utilizing a single 180mg subcutaneous dose of briquilimab [2] - Key objectives include demonstrating proof-of-concept in asthma, assessing early and late asthmatic responses, airway hyperresponsiveness, mast cell depletion, and safety [2][4] Mechanism of Action - Briquilimab functions as a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to c-Kit, leading to mast cell depletion and potentially alleviating inflammatory responses in mast cell-driven diseases [4][5] - The mechanism of mast cell depletion via c-Kit inhibition is considered novel and may address safety issues seen with other c-Kit inhibitors [3]

Originally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising my background in life sciences to assess the potential of novel treatments, including those using CGT, as well as, their capacity to drive shareholders' returns. Thus, as SA analyst, I will be focusing on analysing biotechnology, pharmac ...

REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: Stifel 2024 Healthcare ConferenceConference Dates: November 18 – 19, ...

Exhibit 99.1 Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update REDWOOD CITY, Calif., November 7, 2024 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-39138 JASPER THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- ...

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy cli ...